Trie authors reviewed the medical records of 194 human immunodeficiency virus (HIV)-positive patients newly diagnosed with cryptosporidiosis and all 3,564 patients with newly diagnosed acquired immunodeficiency syndrome (AIDS) at San Francisco General Hospital for the period 1986-1992. The study was designed to address three questions: 1) How do AIDS patients who present with cryptosporidiosis differ from other patients with AIDS? 2) What factors are associated with survival among AIDS patients with newly diagnosed cryptosporidiosis? 3) Does a diagnosis of cryptosporidiosis impact survival after AIDS diagnosis? A total of 194 cases of cryptosporidiosis among HIV-infected patients were identified during the study period. Of the 194 patients, 109 (56%) had no prior diagnosis of AIDS. These 109 patients represented 3.1% of the 3,564 newly diagnosed cases of AIDS in the same period. Among the 134 patients with CD4 T-lymphocyte counts performed within 3 months of Cryptosporidium diagnosis, 34 (25%) had CD4 counts greater than 209 cells/ml. In a multivariate conditional logistic regression model, the incidence of Cryptosporidium was related to ethnicity (for blacks vs. whites, matched odds ratio (OR) = 0.15, 95% confidence interval (Cl) 0.03-0.73), CD4 count (for a CD4 count of s53 cells/ml vs. >53 cells/ml, matched OR = 12.60, 95% Cl 4.01-39.61), and age (for a 10-year increase, matched OR = 0.51, 95% Cl 0.27-0.98). Two factors measured at the time of Cryptosporidium diagnosis were identified as being independently associated with survival (p < 0.001) in the proportional hazards model: CD4 count ^53 cells/ml versus >53 cells/ml (relative hazard = 6.18, 95% Cl 2.99-12.76) and hematocrit £37% versus >37% (relative hazard = 2.27, 95% Cl 1.22-4.22). The median durations of survival in the four subgroups of C/ypfosporfd/um-infected patients defined by these two variables differed significantly from each other (range, 204-1,119 days). Cryptosporidiosis as an initial AIDS-defining diagnosis was associated with an elevated relative hazard of death in comparison with other AIDS-defining diagnoses (relative hazard = 2.01, 95% Cl 1.38-2.93). These data identify the groups of HIV-infected individuals at risk for presentation with symptomatic Cryptosporidium infection; the distinct survival patterns among subgroups of those patients already infected with this parasite; and the survival of AIDS patients with newly diagnosed cryptosporidiosis relative to patients with other AIDS-defining conditions. Such information is necessary for the design of prospective studies, the development of prophylactic strategies, the evaluation of candidate therapies, and the provision of prognostic information to patients.
arrhea which can occur with this infection, although a number have been tried. Numerous reports have suggested that transmission of Cryptosporidium to humans from other infected humans is possible through sexual contact, nonsexual contact (both at home and in the hospital), ingestion of contaminated drinking water or food, or contact with infected pets or animals (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . There are, however, no data with which to estimate the relative importance of any of these potential routes of transmission to human immunodeficiency virus (HTV)-infected individuals. Few data exist with which to develop a risk profile of HTV-infected individuals who are particularly susceptible to infection after exposure to Cryptosporidium. Moreover, it is not yet understood whether cryptosporidiosis represents reactivation of an infection acquired earlier in life or the onset of symptoms caused by recent infection. Throughout this paper, the term "cryptosporidiosis" will refer to either of these presentations.
We carried out an incidence case-control study to examine the characteristics of HTV-infected patients identified as having Cryptosporidium oocysts in their stool. We also examined the factors associated with survival in this group of patients and in comparison with patients with other AIDS-defining conditions.
MATERIALS AND METHODS Data collection for Cryptosporidium-iniected patients
The microbiology laboratory at San Francisco General Hospital maintains a computer-generated record of all clinical specimens sent for parasitologic evaluation. This record was used to identify all patients (n = 234) who had stool specimens in which Cryptosporidium was identified microscopically during the period September 1, 1986 , through September 30, 1992 . Diagnosis of Cryptosporidium was made in the clinical laboratory using cold Kinyoun staining of sediment from formalin ethyl acetate concentration of stool specimens (20) . All available medical records for these patients (n = 210) were reviewed. From this group, all patients whose medical records provided evidence of HTV infection (n = 194) were selected. Evidence of HTV infection included a diagnosis of AIDS or a physician's indication that the patient was infected with HTV.
From each patient's chart, demographic, clinical, and laboratory information was collected using a form that had been developed during a prestudy pilot test. Demographic information obtained included the patient's date of birth, risk factors for transmission of HTV (sexual orientation and the use of injection drugs), date of death or date last known to be alive, ethnic group, and sex. Clinical information obtained included the date of HTV diagnosis (if known), the date(s) and type(s) of other HTV-related infections or malignancies, and the date of diagnosis (if available) of the patient's first AIDS-defining condition. Laboratory information gathered included the date and value of alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels and total bilirubin, hematocrit, and absolute CD4 T-lymphocyte count. The only laboratory results presented in this report are those that were obtained within 3 months of (3 months before to 3 months after) diagnosis with Cryptosporidium (for the cases) or AIDS (for the time-matched controls).
Selection of controls and analytic approach to the case-control study
The Seroepidemiology and Surveillance Branch of the San Francisco Department of Public Health maintains an active surveillance program for patients diagnosed with AIDS as defined by the Centers for Disease Control (21, 22) . The information collected for each patient includes date of birth, sex, ethnic origin, risk factors for acquisition of HTV infection, the date(s) and type(s) of AIDS-defining conditions, values from CD4 cell assays, and the date and cause of death if any. From this registry, all 3,564 patients at San Francisco General Hospital who were newly diagnosed with AIDS between September 1, 1986, and September 30, 1992, were selected.
The variables (obtained from hospital chart review) for the 194 cases with cryptosporidiosis identified from the San Francisco General Hospital microbiology laboratory records were cross-validated with the variables for these same patients recorded in the Department of Public Health AIDS surveillance registry. For three (1.6 percent) of the 194 patients, there were discrepancies as to the mode of HTV transmission. The present analyses classify these three patients using the data for mode of transmission recorded in the AIDS surveillance registry. No other discrepancies in any other variables between the two sources of data were detected.
For each case, a group of eligible controls (a "risk set") was identified. The risk set for a given case included all controls who met the following criteria: 1) the date of AIDS diagnosis was within 30 days of the date of Cryptosporidium identification in the case under investigation; and 2) the date of death of the control (if any) was later than the date of Cryptosporidium identification in the matched case. For each case, five controls were selected randomly through a random-number algorithm using the STATA statistical package (23) . This process was repeated for each of the 194 cases. This method of sampling controls (incidence density sampling) was chosen because it eliminates any possibility of confounding by temporal trends (since the cases and controls are matched on time of diagnosis) if the matched structure of the data is retained in the analysis. This sampling method provides an unbiased estimate of the incidence density ratio and requires no assumptions about constant exposure to putative risk factors over time (24) . The newly diagnosed AIDS patients were chosen as the group from which to sample controls because this group was believed to best represent the accessible study base (25) (26) (27) from which new cases of Cryptosporidium were likely to be identified at the same hospital where the cases were diagnosed. The "perfect" study base from which to form sets of potential controls for each case would have been all HIVinfected patients ahve in San Francisco at the time of identification of each case; however, no such registry exists.
One important feature of incidence density sampling is that patients selected as controls may themselves later become cases (24) . They are properly included in the analysis both as eligible controls, prior to becoming cases themselves, and as cases; as such, the controls represent the "person-time" experience from which the cases occurred. In our study, 12 (1.2 percent) of the 970 controls were later identified as cases.
Differences between the Cryptosporidium-infected patients and the controls with regard to sex, ethnicity, sexual orientation, and the use of injection drugs were examined with matched odds ratios calculated by conditional logistic regression. Differences between the Cryptosporidium-infected group and the comparison group of AIDS patients with regard to continuous variables (age and CD4 count) were examined by nonparametric Kruskal-Wallis analysis of variance (PROC NPAR1WAY in the PC-SAS statistical package) (28) . Additional baseline laboratory results (hematocrit, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and total bilirubin) are presented for the Cryptosporidium-infected patients; comparable data for the individuals diagnosed with AIDS were not available through the registry. Multiple conditional logistic regression was used to examine the joint relation between the variables under investigation and the occurrence of Cryptosporidium infection. Conditional logistic regression analyses were carried out using the CLOGIT option of the STATA statistical package (23) .
Analysis of factors related to survival among the Cryptosporidium patients
In this analysis, survival time was defined as the time from the earliest diagnosis of Cryptosporidium to death or to the last date on which a patient with Cryptosporidium was known to be alive. All living patients were censored as of September 30, 1993 , or as of the last date on which they were documented to be alive (if prior to September 30, 1993) .
For each categorical variable, product-limit (Kaplan-Meier) survival curves were constructed for each level of the variable. Continuous variables were converted into categorical variables by dichotomizing each variable at the median value for the Cryptosporidium-infected population. The log-rank test was used to test for statistical differences in the observed survival patterns (29) . The product-limit analyses were conducted using the LIFETEST option of the STATA statistical package (23) . The data were examined for temporal trends in survival by comparing the differences in survival between the patients diagnosed before and after the median date of the study period, respectively.
The joint influences on survival of all variables identified as significantly related to survival in the product-limit analyses were examined with Cox proportional hazards regression using the COX option of the STATA statistical package (23) . The model was first constructed by creating a saturated model employing all available variables. Variables were removed from the saturated model by backward stepwise regression. At each step, a variable was retained if the significance level of its coefficient was less than 0.20. This moderately high significance level was chosen so as not to exclude, in the intermediate steps of the analysis, any variables with potentially important relations to survival whose effects might be difficult to detect due only to sample size limitations. Additionally, a forward stepwise regression analysis was performed to confirm that the resulting final models in the two approaches were the same. The variables used in the final model were tested for the validity of the assumption of proportional hazards by evaluating the linearity of plots of log {-log(S(f/);} versus log (/,),, where S(t,)j describes the jth survival probability for the ith level of each variable and (t t )j describes the /th survival time for the ith level (30) . A qualitative goodness-of-fit examination of the proportional hazards models was undertaken in two ways. First, the median survival predicted by the final model for each subgroup of patients was compared with the actual median survival observed when the patients were classified on the basis of the risk factors included in the final model. The survival models were also examined for goodness of fit by visual inspection of plots of Martingale and deviance residuals (31) .
Analysis of the impact of a diagnosis of cryptosporidiosis on survival after AIDS diagnosis
In this analysis, survival time was defined as the time from a diagnosis of cryptosporidiosis or AIDS to death or to the last date on which the patient was known to be alive. All living patients were censored as of September 30,1993 , or the date on which they were last documented to be alive (if prior to September 30, 1993) . Two groups of patients with CD4 counts made within 3 months of AIDS diagnosis were examined in this analysis: those for whom cryptosporidiosis was an AIDS-defining diagnosis (n = 69) and those for whom cryptosporidiosis was never known to occur (n -1,390).
The modeling strategy for this analysis was similar to that described above, with the exception that data on continuous covariates such as age and CD4 count were retained in their continuous form (rather than being dichotomized) or transformed as necessary to provide a linear relation to the principal outcome of interest (survival). 
Analysis of risk factors for infection
The characteristics of the 194 Cryptosporidiuminfected patients and the 970 controls are presented in table 1. The incidence of Cryptosporidium was decreased in females relative to males (odds ratio (OR) = 0.38, 95 percent confidence interval (CI) 0.14-1.06), although this difference was not statistically significant. There was a significant decrease in the incidence of Cryptosporidium among AfricanAmericans relative to whites (OR = 0.26, 95 percent CI 0.13-0.53) and a significant increase among Hispanics in comparison with whites (OR = 1.66, 95 percent CI 1.12-2.48). The Cryptosporidium-infected patients were slightly younger than their controls (median ages of 34 years and 37 years, respectively).
In the univariate analysis, there was evidence of a strong interaction between injection drug use and sexual orientation (table 1) . Among those with a history of injection drug use, Cryptosporidium patients were less likely to be heterosexual than were the control patients (OR = 0.04, 95 percent CI 0.01-0.28). This contrasts with the likelihood of being heterosexual among those with no known history of injection drug use (OR = 1.77, 95 percent CI 0.53-5.99).
The median CD4 T-cell count among the Cryptosporidium patients (53 cells/ml) was lower than that found among the controls (164 cells/ml) ( 
Analysis of factors related to survival among the 194 Cryptosporidium patients
In univariate analyses, one clinical variable (a prior AIDS diagnosis) and three laboratory variables (CD4 count, hematocrit, and alkaline phosphatase) measured at the time of Cryptosporidium diagnosis appeared to be strongly related to survival (table 3) .
The proportional hazards analyses identified two variables as significant predictors of survival: CD4 count and hematocrit. The relative hazard for patients with CD4 counts less than or equal to 53 cells/ml was 6.18 (95 percent CI 2.99-12.76) in comparison with those with CD4 counts greater than 53 cells/ml; the relative hazard for patients with a hematocrit less than or equal to 37 percent was 2.27 (95 percent CI 1.22-4.22) in comparison with those with a hematocrit greater than 37 percent. Survival experience was examined after patients were stratified into four groups using these two dichotomous variables (table 4). The observed median duration of survival ranged from 204 days in patients with both CD4 and hematocrit values at or below the population medians for these variables to 1,119 days in those with both values above the population median; the median survival predicted by the model ranged from 213 days to 1,119 days.
Analysis of the impact of a diagnosis of cryptosporidiosis on survival after AIDS diagnosis
The impact of cryptosporidiosis on survival after AIDS diagnosis is presented in table 5. In comparison with the 1,390 AIDS patients who had CD4 counts available and were never known to develop cryptosporidiosis, the relative hazard of death among the 69 patients for whom cryptosporidiosis was an AIDSdefining diagnosis (and for whom CD4 counts were available) was 2.01 (95 percent CI 1.38-2.93). Figure  1 displays survival curves for these two groups (adjusted for CD4 count, age at diagnosis, and date of diagnosis) based on the Cox regression analysis presented in table 5. 
DISCUSSION
The present study provides evidence that HTVinfected patients with Cryptosporidium cysts detected in their stool differ from other AIDS patients with regard to race, sexual orientation, and history of injection drug use. To our knowledge, no previous reports on Cryptosporidium infection have included timematched control patients with which to make such comparisons with AIDS patients. Additionally, the present study demonstrates distinct survival patterns among subgroups of Cryptosporidium-infected patients who are also infected with HTV. These subgroups were defined using a combination of two routinely measured clinical variables (CD4 count and hematocrit) determined at the time of Cryptosporidium diagnosis, which allowed for separation into distinct subgroups. Finally, this investigation documents a significantly elevated risk of death for HIV-positive patients for whom cryptosporidiosis is an initial AIDS diagnosis, something that has not previously been appreciated.
Several of our findings regarding Cryptosporidium patients are consistent with the observations of previous investigators. The age distribution of Cryptosporidium patients reported in the work of Flanigan et al. (32) and McGowan et al. (33) was similar to that of our patients. The patients in our study tended to be younger than the control AIDS patients; previous studies did not provide comparison groups. Similarly, the degree (and variability) of immune suppression (as measured by CD4 counts) was remarkably similar to ours in these other reports (32, 33) . However, our findings that 56 percent of the patients newly diagnosed with Cryptosporidium had no prior AIDSdefining opportunistic infection or malignancy and that 25 percent of the patients had CD4 counts greater than 209 cells/ml have not been noted previously. Taken together, these findings suggest that Cryptosporidium infection may occur earlier in the course of HTV progression than previously reported (32, 33) and that it may resemble, in the timing of its presentation, other AIDS-related conditions, such as tuberculosis, which also can occur before severe states of immunocompromise are reached.
African-Americans infected with HTV appeared to have a substantially lower incidence of Cryptosporidium infection than other ethnic groups in both univariate and multivariate analyses (tables 1 and 2). After adjustment for age, injection drug use, sexual orientation, and CD4 count (table 2), the elevated incidence suggested for Hispanics in the univariate analysis (table 1) was not present. Our data do not define what other factors among these ethnic groups may be responsible for these findings. If symptomatic cryptosporidiosis represents the clinical presentation of infection acquired earlier in life, then individuals who have lived in areas of endemic cryptosporidiosis might be more likely to present with this infection after immunosuppression occurs. The concept of reactivation of latent Cryptosporidium infection has been proposed by others but has not been proven (34) (35) (36) .
There was evidence in our data of a strong interaction between sexual orientation and the use of injection drugs (table 1). One hypothesis explaining such an interaction would be that Cryptosporidium is transmitted from person to person through intimate sexual contact and that homosexual users of injection drugs are more likely to engage in high-risk sexual practices, such as anilingus and unprotected anal intercourse, than homosexuals who do not use injection drugs.
While our data are suggestive of a decreased incidence of presentation with Cryptosporidium among women (table 1), the precision of our estimates was limited by the small number of women in our study. The proportion of women with AIDS in San Francisco is relatively small. The question of sex differences in susceptibility would be better studied in a population with a larger proportion of female patients.
Significant heterogeneity in the survival of HIVinfected persons who present with Cryptosporidium oocysts in stool specimens has been previously reported among limited numbers of patients (33) . The lack of a clear understanding of the relevant factors associated with this survival heterogeneity and the variability in degrees of immunosuppression at the time of presentation make the task of conducting trials of experimental therapies especially difficult. Even in a randomized trial of a proposed treatment (and especially in typically small Phase I trials), it is possible that randomization will create intervention arms with unbalanced pretreatment survival expectations. Such an imbalance could lead to inaccurate estimates of effectiveness when survival is used as a principal outcome (37) . The present study provides a means by which clinical investigators may initially stage Cryptosporidium infection using two widely available clinical measures (CD4 count and hematocrit). Our data on survival provide a starting point with which to stratify enrollees into therapeutic trials, but they do not lessen the need for a more complete understanding of the natural history of this disease. The finding that the relative hazard of death among the newly diagnosed cryptosporidiosis patients is so much higher than that in other newly diagnosed AIDS patients further underscores the urgent need to develop therapeutic agents.
Our study had a number of limitations. All inferences drawn from our data relate to HIV-infected patients who came to the attention of San Francisco General Hospital. We attempt no generalization to patients from other sites where the distribution of risk factors for HTV and Cryptosporidium may be different. Additionally, we had no way of estimating, in our population, the prevalence of asymptomatic or mildly symptomatic carriage of Cryptosporidium infection. A study of such patients would be necessary to identify factors related to initial infection with Cryptosporidium rather than to symptomatic presentation, as was the criterion in our study.
There was no way in the present study to investigate whether the likelihood of having a stool specimen sent for parasitic testing differed between cases and controls by ethnicity, age, sexual orientation, or other variables under investigation. Such a difference in the identification of cases (i.e., a diagnostic bias) would be important if a significant proportion of the controls actually had the outcome of interest (symptomatic cryptosporidiosis) but did not undergo stool testing. We believe that this would be an important issue if the cases and controls came from different institutions. In the present investigation, all cases and controls received care at the same hospital during the same time period, and are thus more likely to have received comparable evaluations.
It is possible that some of the cases experienced a self-limited period of diarrhea. In the pilot study for this project, we attempted to develop a means by which to classify such patients. However, clinic records of subsequent visits were sufficiently incomplete that we could not make a reliable assessment of the persistence of diarrhea or the persistence of oocyst shedding (since subsequent stool specimens were infrequently ordered). If the disease were self-limited in a significant number of patients, observed survival might not be related to cryptosporidiosis. The goal of the present investigation, however, was to provide an estimate of survival at the time of initial symptomatic presentation before the occurrence of subsequent clinical events (such as clearing of the infection).
The severity of Cryptosporidium infection among HIV-positive individuals, our lack of information regarding the principal methods of transmission in this population, the uncertainty as to effective measures with which to prevent transmission, and the lack of effective therapy all mandate additional investigation. The natural history of this infection in HIV-positive individuals should be studied prospectively; the routes of transmission require detailed investigation with molecular typing techniques to identify distinct organisms and their spread in a population; and trials of candidate therapeutic agents must be guided by the knowledge that distinct survival patterns exist among these patients, even without treatment.
